Neoantigen Vaccine Plus Capecitabine as Adjuvant Therapy for Intrahepatic Cholangiocarcinoma After Radical Resection
This study is a single-arm, open-label, exploratory clinical trial, with the primary objective to evaluate the efficacy and safety of the Neoantigen Vaccine plus capecitabine for the treatment of high-intermediate risk recurrent intrahepatic cholangiocarcinoma
Intrahepatic Cholangiocarcinoma
COMBINATION_PRODUCT: Neoantigen Vaccine plus Capecitabine
Incidence of Treatment-Emergent Adverse Events (TEAEs) and Treatment-Related Adverse events (TRAEs), Serious adverse events (SAEs), and grade 3 or higher TRAEs., Safety parameters in this study include clinical symptoms, vital signs, physical examinations, laboratory tests (complete blood count, urinalysis, blood chemistry, coagulation function, etc.). Adverse events (AEs) observed are evaluated according to the NCI-CTCAE version 5.0, including type, incidence, severity, onset and end time, whether they are serious adverse events, and their relationship to the investigational drug., Up to 12 weeks after the last use of the study drug
1 year Overall Survival (OS) rate, The percentage of patients who are still alive one year after the start of the study., up to 1 year|Recurrence-free survival (RFS), Recurrence-free survival (RFS) is defined as the time from initiation of treatment with the first dose to the first documented recurrence (according to RECIST 1.1 criteria) or until the patient's death from any cause, whichever occurs first., up to 2 years
Biomarker analysis (changes in immune cells and regulating immune-related molecules and immune-related indicators in patients before and after treatment), Assess the effects of new antigen vaccines on activating immune cells and regulating immune-related molecules, as well as changes in immune-related indicators in patients before and after treatment., Up to 2 years
This study is a single-arm, open-label, exploratory clinical trial, with the primary objective to evaluate the efficacy and safety of the Neoantigen Vaccine plus capecitabine for the treatment of high-intermediate risk recurrent intrahepatic cholangiocarcinoma